Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2008-05-27
2008-05-27
Mosher, Mary E. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C930S220000, C930S223000, C424S186100, C424S189100, C424S225100, C424S228100
Reexamination Certificate
active
07378234
ABSTRACT:
Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: —providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, —contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, —detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterizing the HCV-peptide from said complex.
REFERENCES:
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: 5683864 (1997-11-01), Houghton et al.
patent: 5723335 (1998-03-01), Hutcherson et al.
patent: 6037135 (2000-03-01), Kubo et al.
patent: 6150087 (2000-11-01), Chien
patent: 6413517 (2002-07-01), Sette et al.
patent: 2003/0162738 (2003-08-01), Egyed et al.
patent: A 1973/2000 (2000-11-01), None
patent: A 805/2001 (2001-05-01), None
patent: 0 468 520 (1991-07-01), None
patent: WO 92/03458 (1992-03-01), None
patent: WO 93/00365 (1993-01-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 94/25601 (1994-11-01), None
patent: WO 95/12766 (1995-05-01), None
patent: WO 95/22317 (1995-08-01), None
patent: WO 95/25122 (1995-09-01), None
patent: WO 95/27733 (1995-10-01), None
patent: WO 95/27901 (1995-10-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 97/30721 (1997-08-01), None
patent: WO 98/15287 (1998-04-01), None
patent: WO 98/16247 (1998-04-01), None
patent: WO 98/18810 (1998-05-01), None
patent: WO 98/37919 (1998-09-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO 98/52581 (1998-11-01), None
patent: WO 98/52962 (1998-11-01), None
patent: WO 99/15259 (1999-04-01), None
patent: WO 99/33488 (1999-06-01), None
patent: WO 99/38528 (1999-08-01), None
patent: WO 99/51259 (1999-10-01), None
patent: WO 99/56755 (1999-11-01), None
patent: WO 99/63941 (1999-12-01), None
patent: WO 00/11186 (2000-03-01), None
patent: WO 00/23105 (2000-04-01), None
patent: WO 00/31542 (2000-06-01), None
patent: WO 00/44775 (2000-08-01), None
patent: WO 01/17551 (2001-03-01), None
patent: WO 01/21189 (2001-03-01), None
patent: WO 01/24822 (2001-04-01), None
patent: WO 01/54719 (2001-08-01), None
patent: WO 01/72782 (2001-10-01), None
patent: WO 01/78767 (2001-10-01), None
patent: WO 01/93903 (2001-12-01), None
patent: WO 01/93905 (2001-12-01), None
patent: WO 02/13857 (2002-02-01), None
patent: WO 02/32451 (2002-04-01), None
patent: WO 02/33127 (2002-04-01), None
patent: WO 02/053185 (2002-07-01), None
patent: WO 02/095027 (2002-11-01), None
patent: WO 03/047602 (2003-06-01), None
patent: WO 03/073097 (2003-09-01), None
patent: WO 2004/014936 (2004-02-01), None
patent: WO 2004/024182 (2004-03-01), None
Jung MC et al. T cell recognition of hepatitis B and C viral antigens. Eur J clin Invest. (Oct. 1994);24(10);641-50.
Koziel MH et al. Hepatisis C Virus (HCV)-Specific Cytotoxic T Lymphocytes Recognize Epitopes in the Core and Envelope Proteins of HCV. J Virol. Dec. 1993;67(12):7522-7532.
Koziel, et al. HCV-specific Cytotoxic T Lymphocytes Recognize Epitopes in the Core and Envelope Proteins of HCV. J Virol. 1993; 67(12):7522-7532.
Betts, et al. Putative Immunodominant Human Immunodeficiency Virus-Specific CD8+ T-Cell Responses Cannot Be Predicted by Major Hiscompatibility Complex Class I Haplotype. J Virol. 2000; 74(19):9144-9151.
Maecker, et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Meth. 2001; 255(1-2):27-40.
“Aluminiumhydroxide,” Röempp, 10thEd., pp. 139-140, 2006 (in German).
Battegay et al., “Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules,”J. Virol., 69(4):2462-2470, 1995.
Bellentani et al., “Epidemiology of hepatitis C virus infection in Italy: the slowly unraveling mystery,”Microbes Infect., 2(14):1757-63, 2000.
Blake et al., “Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes,”J. Exp. Med., 184:121-130, 1996.
Chang et al., “Identification of HLA-A3 and B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C,”J. Immunol., 162:1156-1164, 1999.
Cho et al., “Activation of human neutrophils by a synthetic anti-microbial peptide, KLKLLLLLK-NH2, via cell surface calreticulin,”Eur. J. Biochem., 266:878-885, 1999.
Diepolder et al., “Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection,”J. Virol., 71(8):6011-6019, 1997.
Duenas-Carrera et al., “Enhancement of the immune response generated against hepatitis C virus envelope proteins after DNA vaccination with polyprotein-encoding plasmids,”Biotechnol. Appl. Biochem., 35:205-212, 2002.
Farci and Purcell, “Clinical significance of hepatitis C virus genotypes and quasispecies,”Semin Liver Dis., 20(1):103-26, 2000.
Gruener et al., “Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus,”J. Virol., 75:5550-5558, 2001.
Heile et al., “Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates,”J. Virol., 74(15):6885-6892, 2000.
Hemmer et al., “Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology,”J. Immunol., 160:3631-3636, 1998.
Hemmer et al., “The use of soluble synthetic peptide combinatorial libraries to determine antigen recognition of T cells,”J. Peptide Res., 52:338-345, 1998.
HLA-prevalence studies, In: HLA 1998, (Gjertson and Terasaki, eds.) American Society for Histocompatibility and Immunogenetics, Lenexa, Kansas, pp. 103-263, 1998.
Hoffmann et al., “Mapping of Immunodominant CD4+ T Lymphocyte Epitopes of Hepatitis C Virus Antigens and Their Relevance During the Course if Chronic Infection,”Hepatology, 21(3):632-638, 1995.
Ibe et al., “Identification and characterization of a cytotoxic T cell epitope of hepatitis C virus presented by HLA-B3501 in acute hepatitis,”J. Gen. Virol., 79:1735-1744, 1998.
Inchauspe and Feinstone, “Development of a heptatis C virus vaccine,”Clinics in Liver Disease, 7:243-259, 2003.
Keilholz et al., “Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy,”J. Immunother., 25(2):97-138, 2002.
Koziel et al., “Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV,”J. Virol., 67:7522-7532, 1993.
Koziel et al., “HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release,”J. Clin. Invest., 96:2311-2321, 1995.
Kurokohchi et al., “A novel cytotoxic T-cell epitope presented by HLA-A24 molecule in hepatitis C virus infection,”J. Hepatology, 34:930-935, 2001.
Lamonaca et al., “Conserved Hepatitis C Virus Sequences Are Highly Immunogenic for CD4+ T Cells: Implications for Vaccine Development,”Hepatology, 30(4):1088-1098, 1999.
Lechmann and Liang, “Vaccine development for hepatitis C,”Seminars in Liver Disease, 20:211-226, 2000.
Leroux-Roels et al., “Lymphoproliferative Responses to Hepatitis C Virus Coes, E1, E2, and NS3 in Patients With Chronic Hepatitis C Infection Treated With Inte
Buschle Michael
Habel Andre
Kirlappos Helen
Klade Christoph
Mattner Frank
Fulbright & Jaworski LLP
Intercell AG
Mosher Mary E.
Snyder Stuart W.
LandOfFree
Method for isolating hepatitis C virus peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for isolating hepatitis C virus peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for isolating hepatitis C virus peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2804043